MedTrace Logo

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

NCT04158102 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-01-18

No results posted yet for this study

Summary

This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

Bupivacaine liposome injectable suspension

Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL

Sponsors & Collaborators

  • Nuance Pharma (shanghai) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Bernard Cheung, Doctor · Queen Mary Hospital, Hong Kong

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-07
Primary Completion
2019-12-17
Completion
2019-12-26
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158102 on ClinicalTrials.gov